Experience

Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering of common stock by Portola Pharmaceuticals, Inc. The common stock…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 5,227,272 shares of common stock of Allakos Inc. for…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $150 million SEC-registered common stock and pre-funded warrants…